Cargando…
Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
Programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) blockade is a promising therapy for various cancer types, but most patients are still resistant. Therefore, a larger number of predictive biomarkers is necessary. In this study, we assessed whether a loss-of-function mutation of the interf...
Autores principales: | Vackova, Julie, Piatakova, Adrianna, Polakova, Ingrid, Smahel, Michal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7084912/ https://www.ncbi.nlm.nih.gov/pubmed/32155707 http://dx.doi.org/10.3390/ijms21051806 |
Ejemplares similares
-
CD80 Expression on Tumor Cells Alters Tumor Microenvironment and Efficacy of Cancer Immunotherapy by CTLA-4 Blockade
por: Vackova, Julie, et al.
Publicado: (2021) -
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017) -
Distinct Responsiveness of Tumor-Associated Macrophages to Immunotherapy of Tumors with Different Mechanisms of Major Histocompatibility Complex Class I Downregulation
por: Piatakova, Adrianna, et al.
Publicado: (2021) -
Experimental Combined Immunotherapy of Tumours with Major Histocompatibility Complex Class I Downregulation
por: Grzelak, Adrianna, et al.
Publicado: (2018) -
Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)